IP Library › Granted Patent US 12669505
Granted Patent B2
US 12669505 · App. 17/715,092 · Granted Jun 30, 2026

Detection of desmoglein-2 in cancers of epithelial origin

Inventors: Darrick Carter (Seattle, WA); Jiho Kim (Seattle, WA); Andre Lieber (Seattle, WA)
Assignees: HTD Bio Corp.; University of Washington
G01N33/57545A61K45/06G01N27/44739G01N33/543G01N2333/47
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12669505
App. No.
17/715,092
Granted
Jun 30, 2026
Kind
B2
Abstract

The disclosure provides methods of diagnosing, prognosing and stratifying cancers in a patient, comprising detecting elevated expression of desmoglein-2 (DSG-2) in a sample of the cancer and referencing that level to historic data to determine treatment regimen, stage, and prognosis of a patient.

Claims (16)

1 . A method of treating a subject suffering from a chemo-resistant ovarian cancer, the method comprising:

obtaining an ovarian cancer sample from the subject;

detecting desmoglein-2 (DSG-2) expression in the ovarian cancer sample obtained from the subject;

diagnosing the chemo-resistant ovarian cancer in the subject, wherein a higher amount of DSG-2 expression in the ovarian cancer sample following a treatment with one or more chemotherapeutic agents relative to DSG-2 expression in an ovarian cancer sample obtained from the subject prior to the treatment indicates that the ovarian cancer is chemo-resistant;

administering to the subject an effective amount of a DSG-2 binding reagent, wherein the DSG-2 binding reagent comprises a junction opener; and

administering the one or more chemotherapeutic agents.

2 . The method of claim 1 , wherein the one or more chemotherapeutic agents comprise an anthracycline/platinum-based combination.

3 . The method of claim 1 , wherein the DSG-2 binding reagent is from an adenovirus.

4 . The method of claim 1 , further comprising, determining the amount of DSG-2 expression in the ovarian cancer sample by RNAseq.

5 . The method of claim 1 , further comprising, determining the amount of DSG-2 expression in the ovarian cancer sample by Western blot.

6 . The method of claim 1 , further comprising, determining the amount of DSG-2 expression in the ovarian cancer sample by reverse transcription polymerase chain reaction (RT-PCR).

7 . The method of claim 1 , further comprising, determining the amount of DSG-2 expression in the ovarian cancer sample by a quantitative ELISA.

8 . The method of claim 1 , further comprising, determining the amount of DSG-2 expression in the ovarian cancer sample by staining the ovarian cancer sample with anti-DSG2 antibody.

9 . The method of claim 1 , further comprising, determining the amount of DSG-2 expression in the ovarian cancer sample by detecting an amount of a DSG-2 binding reagent bound to the DSG-2 in the ovarian sample, wherein the DSG-2 binding reagent is conjugated to a dye, a fluorescent molecule or a chemiluminescence molecule.

10 . The method of claim 9 , wherein the DSG-2 binding reagent comprises an anti-DSG2 antibody.

11 . The method of claim 9 , wherein the DSG-2 binding reagent comprises a junction opener.